Clinical Pharmacology in Psychiatry : Bridging the Experimental--Therapeutic Gap

At the International Meetings on Clinical Pharmacology in Psychiatry (IMCPP), the first held in Chicago 1979, the second in Troms6 1980 and now the third in Odense (Hindsgavl), experimental pharmacologists, clinical pharmacologists and clinicians have met for in-depth discussion of various fields of psychopharmacology. Particular aims of these meetings have been to increase the mutual understanding of research strategies and methodological problems in these fields, and to bridge the gap between experimental findings and clinical applications of new knowledge. The 3rd IMCPP, held at Hindsgavl Castle in the western corner of the island Fyn, thus brought together experts from a wide range of fields and from many countries. Nonetheless, a high degree of mutual understanding of principles and problems was achieved, and the 18-20 hours daylight in Denmark in June permitted long and stimulating discussions. The papers presented at the meeting and published in this book illustrate the continuity from experimental research to clinical utilization of psychotropic drugs. Front Matter....Pages i-xviii Front Matter....Pages 1-1 Utilization of psychotropic drugs in Sweden and the other Nordic countries....Pages 3-17 Patterns of use of psychotropic drugs in Spain in an international perspective....Pages 18-31 Heavy drug use among the elderly: prescription surveys in Manitoba....Pages 32-41 To what extent are inter- and intraregional differences in psychotropic drug use explained by demographic and socioeconomic factors?....Pages 42-58 Front Matter....Pages 59-59 Methodology of clinical trials: current issues....Pages 61-67 Practical aspects of the utilization of double-blind trials using adjusted doses of psychotropic drugs....Pages 68-73 Improving reliability and validity of adverse drug reaction assessment in psychopharmacology....Pages 74-82 Clinical evaluation of the cardiac effects of new psychotropic drugs....Pages 83-98 The implications of left ventricular performance for tricyclic antidepressant drug treatment....Pages 99-107 Registration of antidepressant drugs — views of a regulatory agency....Pages 108-113 Phase-4 studies in psychopharmacology — new antidepressant drugs....Pages 114-126 Front Matter....Pages 127-127 Overview: measuring plasma concentrations of psychotherapeutic drugs....Pages 129-135 Possible role of hydroxymetabolites in the action of neuroleptics....Pages 136-149 Radioreceptor assay for measurement of anticholinergic drugs in serum....Pages 150-164 Clinical effects related to the serum concentrations of thioridazine and its metabolites....Pages 165-174 Plasma levels of perphenazine related to clinical effect and extrapyramidal side-effects....Pages 175-181 Saliva haloperidol concentrations in schizophrenic patients: relation to serum haloperidol and prolactin concentrations....Pages 182-189 Front Matter....Pages 191-191 Significance of the serum lithium concentration and the treatment regimen for wanted and unwanted effects of lithium treatment....Pages 193-202 Hydroxy metabolite concentrations: role of renal clearance....Pages 203-216 Stereospecific 10-hydroxylation of nortriptyline — genetic aspects and importance for biochemical and clinical effects....Pages 217-226 Front Matter....Pages 191-191 The fate of amitriptyline and its metabolites, taking into account their binding in plasma....Pages 227-237 Protein binding of imipramine and related compounds....Pages 238-248 Front Matter....Pages 249-249 Relationships between receptor affinities of different antidepressants and their clinical profiles....Pages 251-267 Antidepressants and ∝-adrenoceptors....Pages 268-287 Antidepressants: effects on histaminic and muscarinic receptors....Pages 288-300 Antidepressants and components of the beta adrenoceptor system: studies on zimelidine....Pages 301-312 β-Adrenoceptor agonists enhance the functional activity of brain 5-hydroxytryptamine: relationship to antidepressant activity....Pages 313-326 Effects of antidepressant treatments on ‘whole body’ norepinephrine turnover....Pages 327-338 Association of 3H-imipramine binding with serotonin uptake and of 3H-desipramine binding with norepinephrine uptake: potential research tools in depression....Pages 339-348 Characterization of high-affinity antidepressant binding to rat and human brain....Pages 349-358 Front Matter....Pages 359-359 The human psychopharmacology of peptides related to ACTH and ∝-MSH....Pages 361-376 Clinical psychopharmacology of endorphins....Pages 377-385 GABA receptor agonists: pharmacological spectrum and clinical actions....Pages 386-394 Benzodiazepine receptor-mediated experimental ‘anxiety’ in rhesus monkeys after infusion of 3-carboethoxy-ß-carboline (ß-CCE)....Pages 395-401 Back Matter....Pages 403-413